Jakeccc
Long

If you've been waiting to get long REGN, now is the time.

NASDAQ:REGN   REGENERON PHARMACEUTICALS INC
46 0 2
It got beaten so badly because of some analyst's note saying that REGN's blockbuster eye drug Eylea has been replaced by cheaper rival drugs. First, it was only rumored to be "10%" of total patients, secondly, its rheumatoid arthritis drug "sarilumab" that is under development with Sanofi             is showing promising signs and is now in phase 3. Overall, reaction is a little overblown IMO             , we can expect a bounce from here.
English
English (UK)
English (IN)
Deutsch
Français
Español
Italiano
Polski
Türkçe
Русский
Português
Bahasa Indonesia
Bahasa Melayu
ภาษาไทย
Tiếng Việt
日本語
한국어
简体
台灣
Home Stock Screener Forex Signal Finder Cryptocurrency Signal Finder Economic Calendar How It Works Chart Features House Rules Moderators Website & Broker Solutions Widgets Stock Charting Library Feature Request Blog & News FAQ Help & Wiki Twitter
Profile Profile Settings Account and Billing My Support Tickets Contact Support Ideas Published Followers Following Private Messages Chat Sign Out